We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Drug maker Lupin aims to launch its first biosimilar product and commercialise its first inhalation product in the US in the current fiscal. Addressing shareholders in the company’s Annual Report for 2018-19 ...